Vol CT Advanced Disease Profile Technical Confirmation Feedback

Efforts:
- Dr. Samei reviewed remaining outstanding to-do items
- Mr. O’Donnell noted that cleanup of the Profile is nearly complete
- Some misalignments of test data were sorted out with the help of Drs. Petrick and Obuchowski
  - Updates included adjustments to data, equations, instructions
- Dr. Petrick is finalizing last changes to his data, which will be posted to the QIDW
  - A colleague of Dr. Petrick’s has volunteered to test the Profile to check for technically confirmed readiness
- Mr. O’Donnell to email the current marked-up version of the Profile to Drs. Siegelman and Gavrielides, with cc to Drs. Samei and Jarecha
- Prior to May 10th, Drs. Gavrielides and Siegelman have volunteered to make a line-by-line review of the Profile
- Once all changes are finalized and a clean copy is ready for posting and distribution, an e-ballot will be distributed to eligible BC voting members on May 10th
- Two weeks will be allotted for the vote to provide adequate review time
- Dr. Siegelman moved; seconded by Dr. Samei, to vote on publishing the Profile to the Technically Confirmed stage. The motion was approved and confirmed by Mr. O’Donnell

Voting:
- A majority vote is needed for the Profile to be considered published as technically confirmed
- After voting, negative comments will be discussed as the Profile moves forward
- Any minor issues (typos, minor corrections) can be summarized in a table or log and forwarded to BC members

Next steps:
- The committee to start thinking about the logistics of moving the current Profile toward the claim confirmed stage and beyond ... to patient care
- Would need clinical trial data from patients with actual lesions documented, not only virtual
- Scan and re-scan data needed
- Consideration of how to measure repeatability within subjects in the field would need to be determined; Dr. Obuchowski offered statistical guidance

New Directions for the CT Volumetry BC:
- Dr. Samei discussed the co-chairs shared vision for the future of the biomarker committee, which states, “We are in the variability reduction business for CT lesions to enable better clinical outcomes.”
- This document with other ideas under consideration has been circulated to BC members for review by the next call on May 24th
- Feedback is welcome and any comments will be collated by RSNA Staff: jlisiecki@rsna.org
- BC members are asked to consider what the highest priority should be and what actions must be undertaken to tackle that priority
- Defining what the measurand would be for a new texture (morphology) Profile is needed; Dr. Samei offered to draft a proposal for BC review

Next Call: Thursday, May 24th at 11:30 am CT